Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04292392

Pain Levels and Opioid Usage in Three Nerve Block Cohorts in Primary TKA

Comparison of Pain Levels and Opioid Usage in ACB + Periarticular Block vs. ACB + IPACK Block vs. ACB + IPACK + Periarticular Block in Patients Undergoing Primary TKA

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Louisville · Academic / Other
Sex
All
Age
22 Years – 89 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to compare effect of combined block of ACB (adductor canal block) with IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block and/or Intra-articular block in immediate postoperative and early postop rehabilitation and pain management in patients undergoing primary TKA. The secondary objective is to review both in-hospital and post-discharge pain levels and narcotic usage of primary TKAs, with a minimum 6-week postoperative follow-up.

Conditions

Interventions

TypeNameDescription
OTHERpreop ACB, followed by Intra-articular block during TKA surgeryPreoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts: * Ropivacaine 5mg/ml (49.25ml) * Epinephrine 1mg/ml (0.5ml) * Ketorolac 30mg/ml (1ml) * Clonidine 0.1mg/ml (0.8ml) * Saline 48.45ml
OTHERpreop ACB+IPACK blockPreoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
OTHERpreop ACB+IPACK block, followed by Intra-articular block during TKA surgeryPreoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts: * Ropivacaine 5mg/ml (49.25ml) * Epinephrine 1mg/ml (0.5ml) * Ketorolac 30mg/ml (1ml) * Clonidine 0.1mg/ml (0.8ml) * Saline 48.45ml

Timeline

Start date
2020-04-06
Primary completion
2020-08-15
Completion
2020-09-30
First posted
2020-03-03
Last updated
2020-11-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04292392. Inclusion in this directory is not an endorsement.